Inhibition of N-type calcium channels by fluorophenoxyanilide derivatives

Article abstract of DOI:10.3390/md13042030

A set of fluorophenoxyanilides, designed to be simplified analogues of previously reported ω-conotoxin GVIA mimetics, were prepared and tested for N-type calcium channel inhibition in a SH-SY5Y neuroblastoma FLIPR assay. N-type or Ca_v2.2 channe

Full text of DOI:10.3390/md13042030

Mar. Drugs 2015, 13, 2030-2045; doi:10.3390/md13042030
OPEN ACCESS
marine drugs
ISSN 1660-3397
www.mdpi.com/journal/marinedrugs
Article
Inhibition of N-Type Calcium Channels by
Fluorophenoxyanilide Derivatives
Ellen C. Gleeson 1,2, Janease E. Graham 1,2, Sandro Spiller 1,†, Irina Vetter 3, Richard J. Lewis 3,
Peter J. Duggan 2,4,* and Kellie L. Tuck 1,*
1
School of Chemistry, Monash University, Clayton VIC 3800, Australia;
E-Mails: ellen.gleeson@monash.edu (E.C.G.); janease.graham@gmail.com (J.E.G.);
sandro.spiller@bbz.uni-leipzig.de (S.S.)
2
CSIRO Manufacturing Flagship, Clayton South, VIC 3169, Australia
3
Institute for Molecular Bioscience, The University of Queensland, St Lucia QLD 4072, Australia;
E-Mails: i.vetter@imb.uq.edu.au (I.V.); r.lewis@imb.uq.edu.au (R.J.L.)
4
School of Chemical and Physical Sciences, Flinders University, Adelaide SA 5042, Australia
†
On exchange from Fakultät für Chemie und Mineralogie, Universität Leipzig,
04103 Leipzig, Germany
* Authors to whom correspondence should be addressed; E-Mails: peter.duggan@csiro.au (P.J.D.);
kellie.tuck@monash.edu (K.L.T.); Tel.: +61-3-9545-2560 (P.J.D.); +61-3-9905-4510 (K.L.T.);
Fax: +61-3-9545-2446 (P.J.D.); +61-3-9905-4597 (K.L.T.).
Academic Editor: Alejandro M. Mayer
Received: 21 February 2015 / Accepted: 26 March 2015 / Published: 13 April 2015
Abstract: A set of fluorophenoxyanilides, designed to be simplified analogues of previously
reported ω-conotoxin GVIA mimetics, were prepared and tested for N-type calcium
channel inhibition in a SH-SY5Y neuroblastoma FLIPR assay. N-type or Cav2.2 channel is
a validated target for the treatment of refractory chronic pain. Despite being significantly
less complex than the originally designed mimetics, up to a seven-fold improvement in
activity was observed.
Keywords: N-type calcium channel; Cav2.2; channel blocker; pain; FLIPR

Mar. Drugs 2015, 13
2031
1. Introduction
Neuropathic pain, which results from nerve damage caused by surgery, trauma, infection or disease,
often does not respond to existing therapies [1,2]. Various estimates put the proportion of the world’s
population afflicted by this condition to be at least 3%, with up to 5% of postoperative patients being
affected. Safe and effective therapies for neuropathic pain are therefore a major unmet medical need.
N-Type calcium channels (Cav2.2 channels) are strongly implicated in chronic and neuropathic pain
and their inhibitors have been widely pursued [1–4]. This approach has been best validated by
Ziconotide (Prialt®), a synthetic version of the peptide ω-conotoxin MVIIA found in the venom of a
fish-hunting marine cone snail Conus magnus. This peptide selectively targets Cav2.2 channels and is
one of the very few effective drugs used to treat intractable chronic pain [5]. However, its intrathecal
mode of delivery and narrow therapeutic window make it less than ideal as a treatment option.
We as well as others have been developing small-molecule inhibitors of Cav2.2 channels as possible
alternatives to Ziconotide [6–29]. Recently clinical development of Z160 (1, Figure 1), a reformulated
form of NP118809 [8], was discontinued after Z160 (1) failed to meet the primary endpoint in Phase II
clinical studies [30]. As a result there is only one compound that targets Cav2.2 channels currently in
clinical trials for the treatment of chronic pain, CNV2197944, the structure of which is yet to be
disclosed [24].
Figure 1. Chemical structure of Z160/NP11809 (1).
As part of an ongoing program to develop new small-molecule inhibitors of Cav2.2 channels, the
pharmacophore of ω-conotoxin GVIA, a 27 residue peptide present in the venom of the cone snail
Conus geographus, has been investigated. This peptide binds essentially irreversibly to the Cav2.2
channel, making it unattractive as a therapeutic, however its well-defined structure has facilitated the
development of peptidomimetics. A number of such mimetics have been disclosed [25–29], developed
using the α,β-bond vector strategy described by Bartlett and Lauri [31], combined with interactive
de novo design [32]. In these mimetics the biologically relevant tyrosine, lysine and arginine side chain
mimics are projected from a central scaffold, as illustrated by the anthranilamide derivative (2)
(Figure 2) [27,32]. Guided by the results of a radioligand-displacement assay, it has been concluded
that with these anthranilamide-based mimetics (Compounds 2–4, Figure 2) the optimum length of the
alkyl side chains is n = 7 for the lysine mimic and n = 3 for the arginine mimic. It was also found that
the replacement of the phenol functionality with fluorine is well tolerated [25]. The most potent
fluorinated analogue in this series was found to be the diguanidino compound (3) while the
corresponding diamino compound (4) had comparatively weak activity. This is consistent with
previous results where truncation of the arginine side chain mimic to an amine in ω-conotoxin GVIA
mimetics is typically detrimental to activity at the N-type channel [25–29].

Mar. Drugs 2015, 13
2032
Figure 2. Structures of previously synthesised anthranilamide-based ω-conotoxin GVIA
mimetics (2–4) [25,27].
Figure 3. Analogues 5a–c and 6a–c targeted in this study.

Mar. Drugs 2015, 13
2033
In order to transition conotoxin mimics towards more drug-like compounds, a number of their
physiochemical properties need to be adjusted. Marketed central nervous system (CNS) active drugs,
for example, tend to have much lower molecular weights, percentage polar surface areas, total number
of nitrogen and oxygen atoms, and hydrogen bond acceptors and donors than are found in mimetics
like 2. We have therefore embarked on a program of molecular modifications aimed at improving the
physiochemical properties of this class of conotoxin mimics while retaining activity at the N-type
calcium channel. A major priority has been to reduce overall molecular weight. Encouraged by
favourable results obtained with the simplification of a benzothiazole class of mimetics, which
involved the deletion of one of the amino acid side chain mimics [28], a similar strategy has been
pursued with the anthranilamides. Thus, in the study described here, the effect on activity of the
deletion of the lysine side chain mimic in compounds 2–4 has been investigated, together with the
SAR related to the substitution pattern of the central aromatic ring (ortho, meta or para). The amino
analogues and their corresponding monoguanidino analogues that were synthesised and tested in this
study are shown in Figure 3, compounds 5a–c and 6a–c.
2. Results and Discussion
2.1. Chemistry
The previously described synthetic route to the anthranilamide-based mimics (3 and 4) [25] was
modified to allow incorporation of the chloropropoxybenzamide moiety and its subsequent derivatisation.
The ortho and para phenoxyl anilines (10a [33,34] and 10c [25]) were readily available and the
required meta phenoxyl aniline (10b) was synthesized in two steps from 4-fluorophenyl boronic acid
(7) and meta-nitrophenol (8) via the intermediate phenoxynitrobenzene (9) (Scheme 1).
Scheme 1. Synthesis of meta-(4-fluorophenoxy)aniline (10b). Reagents and conditions:
(a) Cu(OAc)2, Et3N, air, 4 Å molecular sieves, dichloromethane (DCM), room temperature
(RT), 24 h 83%; (b) Pd/C, NH2NH2·H2O, EtOH, RT, 4 h, 95%.
With the required 4-fluorophenoxyanilines (10a–c) in hand, the desired ortho, meta and para amino
phenoxy anilides (5a–c) and monoguanidino phenoxy anilides (6a–c) were synthesised, as outlined in
Scheme 2. Reaction of the phenoxyl aniline (10a–c) with 4-(3-chloropropoxy)benzoic acid [35,36],
using either carbodiimide activation [37] or formation of the acid chloride, gave the desired chloro
compounds (11a–c). Subsequent conversion to the azide (12a–c) with sodium azide, followed by a
transfer-hydrogenation reaction provided the corresponding amines (5a–c). Treatment of amines (5a–c)
with 1H-pyrazole-carboxamidine [38] furnished the phenoxy anilides (6a–c) as hydrochloride salts.

Mar. Drugs 2015, 13
2034
Scheme 2. Synthesis of phenoxy anilides (5a–c and 6a–c). Reagents and conditions:
(a) 4-(3-chloropropoxy)benzoic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDC·HCl), 4-dimethylaminopyridine (DMAP), Et3N, DCM/tetrahydrofuran
(THF), (11a) 47%, (11b) 81% or 4-(3-chloropropoxy)benzoyl chloride, THF, (11c) 70%;
(b) NaN3, dimethyl sulfoxide (DMSO), 70 °C, (12a) 95%, (12b) 99%, (12c) 92%; (c)
Pd/C, NH2NH2·H2O, MeOH, (5a–c) quant.; (d) 1H-pyrazole-1-carboximidine hydrochloride,
N,N-diisopropylethylamine (DIPEA), dimethylformamide (DMF), (6a–c) quant.
2.2. Biology
It has been shown that SH-SY5Y neuroblastoma cells endogenously expressing human Cav2.2
channels allow the rapid screening of potential channel blockers by means of a FLIPR assay [39]. The
synthesised compounds, the amino (5a–c) and the guanidinium (6a–c) analogues, as well as the
anthranilamide-based mimetic (3), were evaluated for their ability to inhibit Cav2.2 calcium responses
in SH-SY5Y cells in the presence of the L-type calcium channel blocker nifedipine. It was found that
Ca2+ ion channel responses elicited by KCl-mediated depolarization were inhibited in a dose-dependent
manner (Table 1). Compound 3 only partially inhibited responses at a concentration of 1 mM, resulting
in an estimated IC50 value of 1452 µM. In contrast, 5a and 5b fully blocked KCl-induced Ca2+
responses with IC50s of 46 µM and 35 µM, respectively. In the guanidinium series, 6a and 6b retained
weaker activity with IC50 values of 124 µM and 185 µM respectively.[40] Both para substituted
compounds, 5c and 6c, were only weakly active and partially inhibited responses with IC50 values of
764 µM and 723 µM, respectively.
Compared to compound 3, compounds 5a–c and 6a–c are significantly less complex and have
molecular weights reduced by 33%–45%. It is encouraging, therefore, to find that all but 5c and 6c are
considerably more active than 3. A relationship between the substitution pattern around the central
aromatic ring and biological activity can also be clearly seen, with the ortho and meta analogues

Mar. Drugs 2015, 13
2035
showing considerably stronger activity than the para analogues. It is also interesting to note that the
amino compounds 5a–b are three to five fold more active than the guanidino compounds 6a–b.
Table 1. Functional inhibition of calcium channels by compounds 3, 5a–c, 6a–c.
Compound
logIC50
~–2.84
–4.34
SEM
0.29
0.01
0.03
0.01
0.02
0.06
0.10
IC50 (µM)
1452 b
46
95% CI (µM)
380–5550
44–48
3 a
5a
6a
5b
6b
5c
6c
–3.90
124 c
35
107–150
33–37
–4.45
–3.73
185
169–203
575–1020
447–1170
~–3.12
764 d
723 e
–3.14
a This compound gave an IC50 of 6 µM in a radioligand displacement assay with 125I-GVIA [25] but it has
b%
since been established that it is less potent in an assay of functional activity at Cav2.2. [29];
Max
c%
d%
e%
inhibition, 15% at 300 µM; Max inhibition, 65% at 300 µM ; Max inhibition, 30% at 300 µM ; Max
inhibition, 19% at 300 µM.
3. Experimental Section
3.1. Chemistry
3.1.1. General Experimental Procedures
Starting materials and reagents were purchased from Sigma-Aldrich (Sydney, Australia) and used
without purification. Solvents were dried, when necessary, using standard methods. Normal phase
flash chromatography was performed on Merck silica gel No. 9385. Spectra were recorded on a Bruker
Av400 or Av600 spectrometer (Fallanden, Switzerland). NMR spectra were referenced to residual
solvent peak [chloroform (δH 7.26, δC 77.2), methanol (δH 4 .87, 3.30, δC 49.0)]. The units for all
‡
coupling constants (J) are in hertz (Hz). Denotes signals only observed in 2D NMR. Mass
spectrometry (APCI) was performed on a Thermo Scientific Q-Exactive FTMS. High-resolution mass
spectra were recorded on a Waters Q-TOF II (Manchester, UK) or Thermo Scientific Q-Exactive
FTMS mass spectrometer (Bremen, Germany). Melting points were recorded on a Stuart Scientific
Melting Point Apparatus SMP3. Infrared spectra were recorded on a Perkin-Elmer RXI FTIR Spectrometer
as thin films. Preparative HPLC was performed on a Waters Prep LC 4000 System using an Alltima
C18 column (22 × 250 mm, 5 micron), detection at 237 nm. Mobile phase 12 mL/min 30%
CAN/H2O/0.2% TFA isocratic for 135 min then 115 min gradient to 100% ACN containing 0.2% TFA.
3.1.2. Synthesis
4-(3-Chloropropoxy)-N-(2-(4-fluorophenoxy)phenyl)benzamide (11a)
Alkyl chloride 11a was synthesised using a modified procedure outlined by Altin et al. [37]. A
solution of 4-(3-chloropropoxy)benzoic acid [36] (1.27 g, 5.91 mmol) in dry THF (50 mL) was stirred
under N2 at room temperature. Triethylamine (0.80 mL, 600 mg, 6.22 mmol) and DMAP (340 mg,
2.79 mmol) were added to the reaction mixture, followed by EDC·HCl (867 mg, 4.54 mmol). After

Mar. Drugs 2015, 13
2036
15 min a solution of the 2-(4-fluorophenoxy)aniline 10a [33,34] (800 mg, 3.94 mmol) in dry DCM
(20 mL) was added and the reaction mixture was stirred under N2 atmosphere at room temperature.
After 48 h the THF was removed in vacuo before the residue was taken up in DCM (50 mL). The
organic layer was washed with saturated NaHCO3 (3 × 50 mL), dried with Na2SO4 and concentrated to
afford a brown oil. Purification by column chromatography (hexanes: EtOAc; 7:2) yielded the alkyl
chloride 11a as a colourless solid (711 mg, 47%). Mp: 101.5–103.5 °C. IR (ATR): 3333 s, 3113 w,
2942 w, 1653 s, 1600 s, 1497 s, 1446 s, 1310 m, 1250 s, 1196 s, 1173 s, 1036 m, 829 m, 764 m cm−1.
1H NMR (400 MHz, CDCl3): δ 8.59 (dd, J = 8.2, 1.5 Hz, 1H), 8.41 (br s, 1H), 7.81–7.77 (m, 2H),
7.19–7.14 (m, 1H), 7.09–7.01 (m, 5H), 6.97–6.94 (m, 2H), 6.83 (dd, J = 8.2, 1.5 Hz), 4.17 (t, J = 6.0 Hz,
2H), 3.75 (t, J = 6.0 Hz, 2H), 2.26 (quin, J = 6.0 Hz, 2H). 13C NMR (100 MHz, CDCl3): 165.0, 161.9,
159.4 (d, J = 241.3 Hz), 152.3, 146.4, 130.0, 129.2, 127.5, 124.3, 124.1, 121.1, 120.5 (d, J = 8.3 Hz),
19
117.3, 116.8 (d, J = 23.5 Hz), 114.7, 64.7, 41.4, 32.2. F NMR (376 MHz, CDCl3): δ −119.4. LRMS
(APCI): m/z 400.1 [M + H]+ (100%), 288.1 [M − C6H4FO]+ (48%). HRMS (APCI): m/z calcd. For
C22H1935ClFNO3 [M + H]+•: 399.1032, found: 399.1032.
4-(3-Azidopropoxy)-N-(2-(4-fluorophenoxy)phenyl)benzamide (12a)
The azide 12a was synthesised according to a procedure outlined by Alvarez et al. [41] Sodium
azide (95 mg, 1.5 mmol) was added to a solution of alkyl chloride 11a (0.45 g, 1.1 mmol) in DMSO
(3 mL) and stirred under N2 atmosphere at 70 °C. After 48 h, the reaction mixture was allowed to cool
and DCM (30 mL) was added. (CAUTION: It is recommended that DCM be substituted with diethyl
ether for larger scale reactions, to avoid the formation of hazardous side products such as
azido-chloromethane and diazidomethane) The organic layer was washed with brine (5 × 50 mL), dried
1
with Na2SO4 and concentrated to provide azide 12a as a pale brown solid (377 mg, 95%). H NMR
spectroscopy deemed this solid to be pure enough to use in the next step. Mp: 69.2–71.2 °C. IR (ATR):
3430 s, 3071 w, 2935 w, 2093 s, 1668 s, 1602 s, 1499 s, 1442 s, 1309 m, 1244 s, 1194 s, 1036 w, 841
1
m, 758 m cm−1. H NMR (400 MHz, CDCl3): δ 8.59 (dd, J = 8.2, 1.6 Hz, 1H), 8.41 (br s, 1H),
7.81–7.77 (m, 2H), 7.18–7.14 (m, 1H), 7.09–7.00 (m, 5H), 6.96–6.93 (m, 2H), 6.83 (dd, J = 8.2, 1.4 Hz,
13
1H), 4.10 (t, J = 6.0 Hz, 2H), 3.52 (t, J = 6.0 Hz, 2H), 2.07 (quin, J = 6.0 Hz, 2H). C NMR
(100 MHz, CDCl3): δ 164.9, 161.7, 159.3 (d, J = 241.4 Hz), 152.3, 146.4, 129.9, 129.1, 127.5, 124.3,
19
124.1, 121.0, 120.4 (d, J = 8.3 Hz), 117.2, 116.7 (d, J = 23.3 Hz), 114.6, 64.9, 48.2, 28.8. F NMR
(376 MHz, CDCl3): δ −119.4. LRMS (APCI): m/z 407.2 [M + H]+ (100%), 204.1 [M − C10H8N3O2]+
(39%), 381.2 [M − N2 + 3H]+ (26%). HRMS (APCI): m/z calcd. For C22H19FN4O3 [M]+•: 406.1436,
found: 406.1438.
4-(3-Aminopropoxy)-N-(2-(4-fluorophenoxy)phenyl)benzamide (5a)
A solution of azide 12a (100 mg, 0.25 mmol), 10% Pd/C (12 mg) and hydrazine monohydrate
(30 µL, 30 mg, 0.62 mmol) in MeOH (3 mL) was vigorously stirred under N2 at room temperature.
After 20 min, the reaction mixture was filtered through Celite™ and concentrated to provide the
amino compound 5a as yellow oil in a quantitative crude yield. A small amount was purified by
reversed-phase HPLC to give a sample for biological testing. IR (ATR): 3432 br, 3071 w, 2942 w,
1
2873 w, 1653 s, 1601 s, 1493 s, 1378 m, 1248 s, 1203 s, 1173 s, 838 m, 758 m cm−1. H NMR

Mar. Drugs 2015, 13
2037
(600 MHz, CD3OD): δ 7.90–7.89 (m, 1H), 7.76–7.74 (m, 2H), 7.18–7.17 (m, 2H), 7.05–6.99 (m, 7H),
13
4.08 (t, J = 6.2 Hz, 2H), 2.81 (t, J = 7.0 Hz, 2H), 1.95–1.91 (m, 2H). C NMR (150 MHz, CD3OD):
δ 168.2, 163.5, 160.7 (d, J = 238.9 Hz), 154.3, 150.8, 130.5, 130.4, 127.6, 127.4, 126.7, 125.0, 120.8
19
(d, J = 7.8 Hz), 120.0, 117.2 (d, J = 23.6 Hz), 115.3, 67.3, 39.6, 33.3. F NMR (376 MHz, CD3OD):
δ −120.5. LRMS (APCI): m/z 381.2 [M + H]+ (50%), 380.2 [M]+ (100%). HRMS (APCI): m/z calcd.
For C22H21FN2O3 [M]+•: 380.1531, found: 380.1532.
N-(2-(4-Fluorophenoxy)phenyl)-4-(3-guanidinopropoxy)benzamide hydrochloride (6a)
The guanidinylated compound 6a was synthesized according to a modified procedure by
Bernatowicz et al. [38]. Amine 5a (102 mg, 0.24 mmol), DIPEA (42 µL, 31 mg, 0.24 mmol),
1H-pyrazole-1-carboximidine hydrochloride (35 mg, 0.24 mmol) and DMF (2 mL) were combined and
stirred vigorously under N2 atmosphere at room temperature. After 18 h TLC analysis revealed that
starting material remained, additional 1H-pyrazole-1-carboximidine hydrochloride (9 mg, 0.06 mmol)
and DIPEA (10 µL, 8 mg, 0.06 mmol) were added. After a further 24 h the solvent was removed in
vacuo to yield the guanidinylated compound 6a as crystalline product. This solid was dissolved in
MeOH (1 mL) and the product precipitated by addition of Et2O (10 mL). After removal of the residual
solvent the product was obtained as a crystalline solid (47 mg, 39%) IR (ATR): 3307 br s, 3251 br s,
3139 br s, 1643 s, 1601 s, 1497 s, 1443 s, 1245 s, 1196 s, 1174 s, 840 m, 759 m cm−1. 1H NMR (400 MHz,
CD3OD): δ 7.88–7.85 (m, 1H), 7.78–7.76 (m, 2H), 7.21–7.18 (m, 2H), 7.07–6.98 (m, 6H), 6.97–6.94
13
(m, 1H), 4.13 (t, J = 5.9 Hz, 2H), 3.41 (t, J = 6.8 Hz, 2H), 2.11-2.05 (m, 2H). C NMR (100 MHz,
CD3OD): δ 168.2, 163.2, 160.2 (d, J = 239 Hz), 158.7, 154.4, 151.0, 130.5, 130.4, 127.9, 127.6, 126.9,
125.0, 120.8 (d, J = 8.3 Hz), 120.1, 117.2 (d, J = 23.4 Hz), 115.4, 66.3, 39.5, 29.5. 19F NMR (376 MHz,
CD3OD): δ −120.6. LRMS (APCI): m/z 422.2 [M]+ (62%), 380.15 [M − CH2N2]+ (100%). HRMS
(ESI): m/z calcd. For C23H23FN4O3 [M]+•: 422.1749, found: 422.1750.
1-(4-Fluorophenoxy)-3-nitrobenzene (9)
The fluoro diaryl ether 9 was synthesised according to a general procedure outlined by Evans et al. [42]
4-Fluorophenyl boronic acid 7 (300 mg, 2.16 mmol), m-nitrophenol 8 (200 mg, 1.44 mmol), Cu(OAc)2
(260 mg, 1.44 mmol) and freshly activated powdered 4 Å molecular sieves were added to dry DCM
(15 mL). Et3N (1.0 mL, 730 mg, 7.19 mmol) was then added to the reaction mixture. The reaction left
open to air through a drying tube and stirred at room temperature, and reaction progress was monitored
by TLC (hexanes: EtOAc; 30:1). After 24 h, the resulting slurry was filtered through Celite™ and
concentrated to give a brown oil. The crude product was purified by flash column chromatography
(hexanes: EtOAc; 30:1) to give the fluoro diaryl ether 9 as a yellow oil (280 mg, 83%). IR (ATR):
1526 s, 1497 s, 1473 s, 1352 s, 1212 s, 1187 s, 811 s, 734 s cm−1; 1H NMR (400 MHz, CDCl3): δ 7.93
(ddd, J = 8.2, 2.3, 0.9 Hz, 1H), 7.75 (t, J = 2.3 Hz, 1H), 7.48 (t, J = 8.2 Hz, 1H) 7.29 (ddd, J = 8.2, 2.3,
0.9 Hz, 1H), 7.13–7.08 (m, 2H), 7.07–7.02 (m, 2H). 13C NMR (100 MHz, CDCl3) 159.8 (d, J = 242.4 Hz),
159.0, 151.3, 149.5, 130.5, 123.8, 121.7 (d, J = 8.4 Hz), 117.8, 117.1 (d, J = 23.2 Hz), 112.4. 19F NMR
(376 MHz, CDCl3): δ −118.1. LRMS (APCI): m/z 234.1 [M + H]+ (100%), 204.1 [M − O2 + 2H]+
(32%), 188.1 [M − NO2]+ (24%). HRMS (APCI): m/z calcd. for C12H10FNO3 [M + H]+: 234.0561,
found: 234.0562.

Mar. Drugs 2015, 13
2038
3-(4-Fluorophenoxy)aniline (10b)
The m-aniline 10b was prepared following a procedure similar to that of Bavin et al. [43] Hydrazine
monohydrate (790 mg, 0.77 mL, 16 mmol) was added to a deoxygenated mixture of the nitroarene 9
(0.50 g, 2.1 mmol), 10% Pd/C (50 mg) and EtOH (25 mL). This reaction mixture was then refluxed
under N2 until TLC analysis (hexanes:EtOAc; 4:1) showed no starting material (typically 4 h). The
reaction mixture was allowed to cool, filtered through Celite™, concentrated in vacuo and the
colourless residue purified by column chromatography (hexanes: EtOAc; 4:1) to yield the m-aniline 10b
as a colourless oil (410 mg, 95%). All spectral data was in accordance with that in the literature [44].
IR (ATR): 3462 s, 3317 s, 1619 m, 1584 m, 1485 s, 1282 m, 1193 s, 1141 s, 832 m, 772 m cm−1.
1H NMR (400 MHz, CDCl3): δ 7.08 (t, J = 8.0, 1H) 7.04–6.96 (m, 4H) 6.42 (ddd, J = 8.0, 2.2, 0.8 Hz,
1H), 6.35 (ddd, J = 8.0, 2.2, 0.8, 1H), 6.30 (t, J = 2.2 Hz, 1H), 3.70 (bs, 2H). 13C NMR (100 MHz,
CDCl3): δ 159.0, 158.7 (d, J = 239.8 Hz), 152.9, 148.2, 130.5, 120.8 (d, J = 8.3 Hz), 116.3 (d, J = 23.1 Hz),
19
110.1, 108.3, 105.0. F NMR (376 MHz, CDCl3): δ −120.5. LRMS (APCI): m/z 204.1 [M + H]+
(100%). HRMS (APCI): m/z calcd. for C12H10FNO [M + H]+: 204.0819, found: 204.0820.
4-(3-Chloropropoxy)-N-(3-(4-fluorophenoxy)phenyl)benzamide (11b)
The alkyl chloride 11b was synthesised using a modified procedure outlined by Altin et al. [37]. A
solution of 4-(3-chloropropoxy)benzoic acid [33,34] (910 mg, 4.24 mmol), in dry THF (50 mL) was
stirred under N2 at at room temperature. Et3N (0.87 mL, 630 mg, 6.22 mmol), and DMAP (340 mg,
2.79 mmol) were then added to the reaction mixture, followed by EDC·HCl (867 mg, 4.53 mmol).
After 15 min, a solution of the 3-(4-fluorophenoxy)aniline 10b (575 mg, 2.83 mmol) in dry DCM
(20 mL) was added, and the reaction mixture was stirred under a N2 atmosphere at room temperature.
After 48 hours the THF was removed in vacuo before being taken up into DCM (50 mL). The organic
layer was then washed with NaHCO3 (3 × 50 mL), dried with Na2SO4 and concentrated to afford a
light brown oil. Purification by column chromatography (hexanes: EtOAc; 7:2) yielded the alkyl
chloride 11b as a colourless solid (917 mg, 81%). Mp: 116.5–117.0 °C. IR (ATR): 3366 s, 1652 s,
1601 s, 1528 m, 1500 s, 1442 s, 1267 m, 1246 s, 1196 s, 846 m, 773 s cm−1. 1H NMR (400 MHz,
CDCl3): δ 7.82–7.89 (m, 2H), 7.75 (bs, 1H), 7.35–7.27 (m, 3H), 7.06–7.00 (m, 4H), 6.98–6.94 (m, 2H),
6.74 (dt, J = 7.2, 2.0 Hz, 1H), 4.18 (t, J = 6.0 Hz, 2H), 3.76 (t, J = 6.0 Hz, 2H), 2.27 (quin, J = 6.0 Hz,
2H). 13C NMR (100 MHz, CDCl3): δ 165.2, 161.9, 159.1 (d, J = 240.4 Hz), 158.5, 152.7, 139.7, 130.3,
129.1, 127.3, 121.0 (d, J = 8.3 Hz), 116.5 (d, J = 23.0 Hz), 114.8, 144.7, 114.1, 110.2, 64.7, 41.4, 32.2.
19F NMR (376 MHz, CDCl3): δ −120.2. LRMS (APCI): m/z 400.1 [M + H]+ (100%). HRMS (APCI):
m/z calcd. for C22H20ClFNO3 [M + H]+: 400.1110, found: 400.1113.
4-(3-Azidopropoxy)-N-(3-(4-fluorophenoxy)phenyl)benzamide (12b)
The azide 12b was synthesised according to a procedure outlined by Alvarez et al. [41]. Sodium
azide (219 mg, 3.38 mmol) was added to a solution of the alkyl chloride 11b (900 mg, 2.25 mmol) in
DMSO (4 mL) and stirred under N2 at 70 °C. After 48 h, the reaction was allowed to cool and DCM
(40 mL) was added. (CAUTION: It is recommended that DCM be substituted with diethyl ether for
larger scale reactions, to avoid the formation of hazardous side products, such as azido-chloromethane

Mar. Drugs 2015, 13
2039
and diazidomethane) The organic layer was washed with brine (5 × 100 mL), dried with Na2SO4 and
concentrated to provide the azide 12b as a colourless solid (902 mg, 99%), which was deemed
1
sufficiently pure by H NMR spectroscopy for use in the next step. Mp: 104.6–106.2 °C. IR (ATR):
3366 s, 2104 s, 1640 s, 1593 s, 1499 s, 1441 s, 1248 s, 1199 s, 848 m, 770 m cm−1. 1H NMR (400 MHz,
CDCl3): δ 7.82–7.79 (m, 2H), 7.76 (bs, 1H), 7.35–7.27 (m, 3H), 7.06–7.00 (m, 4H), 6.97–6.93 (m, 2H),
6.74 (dt, J = 7.0, 2.2 Hz, 1H), 4.11 (t, J = 6.3 Hz, 2H), 3.53 (t, J = 6.3 Hz, 2H), 2.08 (quin, J = 6.3 Hz,
2H). 13C NMR (100 MHz, CDCl3): δ 165.3, 161.9, 159.1 (d, J = 240.5 Hz), 158.6, 152.7, 139.7, 130.3,
129.1, 127.3, 121.0 (d, J = 8.4 Hz), 116.5 (d, J = 23.2 Hz), 114.8, 114.7, 114.2, 110.2, 65.0, 48.3, 28.9.
19F NMR (376 MHz, CDCl3): δ −120.2. LRMS (APCI): m/z 407.2 [M + H]+ (100%). HRMS (APCI):
m/z calcd. For C22H20FN4O3 [M + H]+: 407.1514, found: 407.1514.
4-(3-Aminopropoxy)-N-(3-(4-fluorophenoxy)phenyl)benzamide (5b)
A solution of the azide 12b (100 mg, 0.25 mmol), 10% Pd/C (12 mg) and hydrazine monohydrate
(30 µL, 30 mg, 0.62 mmol) in MeOH (3 mL) were vigorously stirred under a N2 atmosphere at room
temperature. After 20 mins, the reaction mixture was filtered through Celite™ and concentrated to
provide the amino compound 5b as a colourless oil in a quantitative crude conversion. IR (ATR): 3280
br s, 1647 s, 1597 m, 1540 m), 1484 s, 1244 s, 1195 s, 837 s, 779 s, 760 s, 684 s cm−1.1H NMR (400 MHz,
CD3OD): δ 7.90–7.87 (m, 2H), 7.45 (t, J = 2.0 Hz, 1H), 7.39 (ddd, J = 8.0, 2.1, 1.0 Hz, 1H), 7.31
(t, J = 8.0 Hz, 1H), 7.13–7.01 (m, 6H), 6.73 (ddd, J = 8.0, 2.1, 1.0 Hz, 1H), 4.13 (t, J = 6.6 Hz, 2H),
2.84 (br t, J = 6.6 Hz, 2H), 1.96 (quin, 6.6 Hz, 2H). 13C NMR (100 MHz, CD3OD): δ 168.4, 163.5,
160.3 (d, J = 238.9 Hz), 159.5, 154.3, 141.6, 130.9, 130.6, 128.0, 121.9 (d, J = 8.3 Hz), 117.3 (d,
19
J = 23.5 Hz), 116.7, 115.3, 114.9, 112.0, 67.3, 39.6, 33.0. F NMR (376 MHz, CD3OD): δ −120.5.
LRMS (APCI): m/z 380.2 [M]+ (100%), 381.2 [M + H]+ (41%). HRMS (APCI): m/z calcd. For
C22H21FN2O3 [M]+: 380.1532, found: 380.1531.
N-(3-(4-Fluorophenoxy)phenyl)-4-(3-guanidinopropoxy)benzamide hydrochloride (6b)
The guanidinylated compound 6b was synthesised according to a modified procedure by
Bernatowicz et al. [38]. The amine 5b (47 mg, 0.12 mmol), DIPEA (35 µL, 26 mg, 0.20 mmol),
1H-pyrazole-1-carboximidine hydrochloride 27 (25 mg, 0.17 mmol) and DMF (2 mL) were added to a
flask and stirred vigorously under a nitrogen atmosphere at room temperature. After 18 h, the solvent
was removed in vacuo to yield the guanidinylated compound 6b as a colourless solid in quantitative
conversion. IR (ATR): 3244 br s, 3150 br s, 1651 s, 1592 s, 1503 s, 1479 s, 1249 s, 1210 m, 1171 s,
1
826 m, 791 m, 692 m cm−1. H NMR (400 MHz, CD3OD): δ 7.92–7.88 (m, 2H), 7.47 (t, J = 2.2 Hz,
1H), 7.41 (ddd, J = 8.1, 2.2, 0.9 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 7.11–7.01 (m, 6H), 6.72 (ddd,
J = 8.1, 2.2, 0.9 Hz, 1H), 4.16 (t, J = 6.3 Hz, 2H), 3.42 (t, J = 6.3 Hz, 2H), 2.09 (quin, J = 6.3 Hz, 2H).
13C NMR (100 MHz, CD3OD): 168.3, 163.2, 160.3 (d, J = 239.0 Hz), 159.9, 158.8, 154.3, 141.6,
130.9, 130.7, 128.4, 121.9 (d, J = 8.4 Hz), 117.3 (d, J = 23.3 Hz), 116.7, 115.3, 115.0, 112.0,
19
66.3, 39.6, 29.6. F NMR (376 MHz, CD3OD): δ −120.5. LRMS (APCI): m/z 422.2 [M]+ (32%),
381.2 [M − CHN2]+ (35%), 380.2 [M − CH2N2]+ (100%). HRMS (APCI): m/z calcd. For C23H23FN4O3
[M]+: 422.1749, found: 422.1749.

Mar. Drugs 2015, 13
2040
4-(3-Chloropropoxy)-N-(4-(4-fluorophenoxy)phenyl)benzamide (11c)
4-(3-Chloropropoxy)benzoic acid (790 mg, 3.68 mmol) was taken up into SOCl2 (2.00 mL, 3.28 g,
27.5 mmol) and the reaction mixture was stirred for 30 min. Excess SOCl2 was removed under a
stream of N2 to provide an acid chloride intermediate. A solution of 4-(4-fluorophenoxy)aniline 10c
(650 mg, 3.20 mmol) in dry THF (35 mL) was added, and the reaction mixture was stirred at room
temperature for 18 h. The THF was removed in vacuo, and the resultant solid was taken up into EtOAc
(60 mL) and washed with sat. NaHCO3 (3 × 100 mL). The organic layer was dried with Na2SO4 and
concentrated to afford the crude alkyl chloride 11c as a brown solid. The solid was recrystallised from
hot EtOAc to give the desired alkyl chloride 11c as a colourless solid (900 mg, 70%). Mp: 147.3–148.1 °C.
IR (ATR): 3338 s, 1642 s, 1607 m, 1496 s, 1259 s, 852 s, 833 s, 816 s, 761 s cm−1. 1H NMR (400 MHz,
CDCl3): δ 7.88–7.84 (m, 2H), 7.71 (br s, 1H), 7.61–7.58 (m, 2H), 7.07–6.97 (m, 8H), 4.22 (t, J = 6.0 Hz,
13
2H), 3.79 (t, J = 6.0 Hz, 2H), 2.30 (quin, J = 6.0 Hz, 2H). C NMR (100 MHz, CDCl3): δ 165.3,
161.9, 158.9‡ (d, J = 239.7 Hz), 154.2, 153.4‡, 133.7, 129.1, 127.4, 122.2, 120.2 (d, J = 8.2 Hz), 119.3,
116.4 (d, J = 23.1 Hz), 114.7, 64.7, 41.5, 32.2. 19F NMR (376 MHz, CDCl3): δ −120.8. LRMS (APCI):
m/z 400.1 [M + H]+ (75%), 399.1 [M]+ (100%). HRMS (APCI): m/z calcd. for C22H19ClFNO3 [M]+:
399.1032, found: 399.1032.
4-(3-Azidopropoxy)-N-(4-(4-fluorophenoxy)phenyl)benzamide (12c)
The azide 12c was synthesised according to a procedure outlined by Alvarez et al. [41]. Sodium
azide (63 mg, 0.97 mmol) was added to a solution of the alkyl chloride 11c (300 mg, 0.752 mmol) in
DMSO (4 mL) and stirred under N2 at 70 °C. After 48 h, the reaction mixture was cooled and DCM
(40 mL) was added. (CAUTION: It is recommended that DCM be substituted with diethyl ether for
larger scale reactions, to avoid the formation of hazardous side products, such as azido-chloromethane
and diazidomethane) The organic layer was washed with brine (5 × 100 mL), dried with Na2SO4 and
concentrated to provide the azide 12c as a colourless solid (279 mg, 92%), which was deemed
1
sufficiently pure by H NMR spectroscopy for use in the next step. Mp: 120.7–122.0 °C. IR (ATR):
1
3325 s, 2099 s, 1648 s, 1605 m, 1494 s, 1250 s, 1208 s, 828 s, 764 m cm−1. H NMR (400 MHz,
CDCl3): δ 7.86–7.82 (m, 2H), 7.68 (br s, 1H), 7.60–7.56 (m, 2H), 7.05–6.95 (m, 8H), 4.13 (t, J = 6.0 Hz,
13
2H), 3.54 (t, J = 6.0 Hz, 2H), 2.09 (quin, J = 6.0 Hz, 2H). C NMR (100 MHz, CDCl3): δ 165.3,
161.8, 158.8‡ (d, J = 261.0 Hz), 154.3, 153.4‡, 133.7, 129.1, 127.4, 122.2, 120.2 (d, J = 8.3 Hz), 119.3,
116.4 (d, J = 23.2 Hz), 114.7, 65.0, 48.3, 28.9. 19F NMR (376 MHz, CDCl3): δ −120.8. LRMS (APCI):
m/z 406.1 [M]+ (100%). HRMS (APCI): m/z calcd. for C22H19FN4O3 [M]+: 406.1436, found: 406.1438.
4-(3-Aminopropoxy)-N-(4-(4-fluorophenoxy)phenyl)benzamide (5c)
A solution of the azide 11c (100 mg, 0.25 mmol), 10% Pd/C (12 mg) and hydrazine monohydrate
(30 µL, 30 mg, 0.62 mmol) in MeOH (3 mL) were vigorously stirred under a N2 atmosphere at room
temperature. After 20 mins, the reaction mixture was filtered through Celite™ and concentrated to
provide the amino compound 5c as a yellow oil in a quantitative crude conversion. IR (ATR): 3307 m,
1
3282 m, 1632 s, 1606 m, 1494 s, 1248 m, 1208 s, 820 s, 758 s cm−1. H NMR (400 MHz, CD3OD):
δ 7.92–7.89 (m, 2H), 7.66–7.62 (m, 2H), 7.10–6.95 (m, 8H), 4.14 (t, J = 6.2 Hz, 2H), 2.84 (t, J = 7.0 Hz,

Mar. Drugs 2015, 13
2041
2H), 2.00–1.93 (m, 2H). 13C NMR (100 MHz, CD3OD): δ 168.3, 163.5, 160.1 (d, J = 238.7 Hz), 155.5,
154.9, 135.5, 130.5, 128.1, 124.2, 121.2 (d, J = 8.1 Hz), 119.8, 117.2 (d, J = 23.3 Hz), 115.3, 67.3,
39.6, 33.3. 19F NMR (376 MHz, CD3OD): δ −121.0. LRMS (APCI): m/z 381.2 [M + H]+ (28%), 380.2
[M + H]+ (100%), 323.1 [M − C3H7N]+ (34%). HRMS (APCI): m/z calcd. for C22H21FN2O3 [M]+:
380.1531, found: 380.1533.
N-(4-(4-Fluorophenoxy)phenyl)-4-(3-guanidinopropoxy)benzamide hydrochloride (6c)
The guanidinylated compound 6c was synthesised according to a modified procedure by
Bernatowicz et al. [38]. The amine 5c (47 mg, 0.12 mmol), DIPEA (35 µL, 26 mg, 0.20 mmol),
1H-pyrazole-1-carboximidine hydrochloride (25 mg, 0.17 mmol) and DMF (2 mL) were added to a
flask and stirred vigorously under a nitrogen atmosphere at room temperature. After 18 h, the solvent
was removed in vacuo to yield the guanidinylated compound 6c as a yellow oil with quantitative
conversion. IR (ATR): 3272 m, 3185 m, 1631 s, 1601 s, 1495 s, 1437 s, 1393 s, 1247 s, 1208 s, 1177 s,
839 m, 759 m. 1H NMR (600 MHz, CD3OD): δ 7.94–7.92 (m, 2H), 7.65–7.63 (m, 2H), 7.10–6.99 (m,
13
6H), 6.98–6.95 (m, 2H), 4.16 (t, J = 5.9 Hz, 2H), 3.43 (t, J = 6.8 Hz, 2H), 2.13–2.07 (m, 2H). C
NMR (150 MHz, CD3OD): δ 168.2, 163.1, 159.5 (d, J = 240.9 Hz), 158.7, 155.5, 154.9, 135.4, 130.6,
19
128.3, 124.2, 121.2 (d, J = 8.0 Hz), 119.8, 117.2 (d, J = 24.1 Hz), 115.3, 66.3, 39.5, 29.6. F NMR
(376 MHz, CD3OD): δ −120.9. LRMS (APCI): m/z 422.2 [M]+ (14%), 381.2 [M − CN2H]+ (30%), 380.2
[M − CH2N2]+ (100%), 323.1 [M-C3H9N3]+ (31%). HRMS (APCI): m/z calcd. for C23H23FN4O3 [M]+:
422.1749, found: 422.1750.
3.2. Biology
Fluorescence Measurement of Calcium Responses
SH-SY5Y cells were plated at a density of 30,000–50,000 cells/well on 384-well black-walled
imaging plates and loaded for 30 min at 37 °C with Calcium 4 no-wash dye (Molecular Devices,
Sunnyvale, CA, USA) diluted in physiological salt solution (PSS; composition: 140 mM NaCl,
11.5 mM glucose, 5.9 mM KCl, 1.4 mM MgCl2, 1.2 mM NaH2PO4, 5 mM NaHCO3, 1.8 mM CaCl2,
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4). Calcium responses, elicited
by addition of 90 mM KCl and 5 mM CaCl2 in the presence of 10 µM nifedipine, were measured using
a FLIPRTETRA fluorescent plate reader (excitation, 470–495 nm; emission, 515–575 nm) after 5 min
pre-treatment with test compounds. Fluorescent responses were plotted as response over baseline using
ScreenWorks (Molecular Devices, version 3.1.1.4). Concentration-response curves of Calcium responses,
normalized to control responses, were generated using GraphPad Prism (Version 4.00, San Diego, CA,
USA) using a 4-parameter Hill equation with variable Hill slope and bottom >0 fitted to the data.
4. Conclusions
Despite being significantly less complex than the originally designed anthranilamide ω-conotoxin
GVIA mimetics (e.g., 2), the simplified fluorophenoxyanilides described here (5a–c and 6a–c) show
enhanced activity in the SH-SY5Y FLIPR assay. The compounds with para-substitution around the
central ring (5c and 6c) were found to have the weakest activity, suggesting that some type of

Mar. Drugs 2015, 13
2042
pre-organisation through restricted rotation might enhance the activity of the ortho and meta analogues
(5a, 5b, 6a and 6b). It is also unusual for the amines to be more active than the guanidines in this class
of channel blocker. While primary amines typically do not make good drugs, this observation does
open the possibility of developing N-type channel blockers capable of crossing the blood brain barrier.
Compounds bearing very strongly basic functional groups like guanidine are unlikely to cross the
blood brain barrier [45] whereas there are many CNS-active drugs that bear tertiary amines. The mode
of action of the compounds reported here is currently being investigated in patch clamp electrophysiology
experiments, the results of which will be reported in due course.
Acknowledgments
The Monash-CSIRO Collaborative Research Support Scheme, Monash University and CSIRO are
acknowledged for funding, as well as Monash University for providing J.E.G., with a Monash
Graduate Scholarship and CSIRO for providing J.E.G., a scholarship top-up. This work was also
supported by a NHMRC Program Grant (569927), NHMRC Australian Biomedical Postdoctoral
Fellowship (569918, IV) and NHMRC Fellowship (APP1019761, RJL).
Author Contributions
E.C.G. synthesised compounds 5a–c and 6a–c, J.E.G contributed to the initial synthetic strategy for
compounds 5a and 6a, S.S. synthesised compound 6a, I.V. performed the FLIPR experiments and
assisted with drafting of the manuscript, R.J.L. assisted with the FLIPR experiments and with drafting
of manuscript, P.J.D. jointly conducted the channel blocker development, synthetic design, drafting of
manuscript, K.L.T. jointly conducted the channel blocker development, synthetic design, drafting
of manuscript.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Vink, S.; Alewood, P.F. Targeting voltage-gated calcium channels: Developments in peptide and
small-molecule inhibitors for the treatment of neuropathic pain. Br. J. Pharmacol. 2012, 167,
970–989.
2. Altier, C.; Zamponi, G.W. Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends
Pharmacol. Sci. 2004, 25, 465–470.
3. Lee, M.S. Chapter four—Recent progress in the discovery and development of N-type calcium
channel modulators for the treatment of pain. In Progress in Medicinal Chemistry; Lawton, G.,
Witty, D.R., Eds.; Elsevier: Oxford, UK, 2014; Volume 53, pp. 147–186.
4. Perret, D.; Luo, Z.D. Targeting voltage-gated calcium channels for neuropathic pain management.
NeuroRX 2009, 6, 679–692.
5. Pope, J.E.; Deer, T.R. Ziconotide: A clinical update and pharmacologic review. Exp. Opin.
Pharmacother. 2013, 14, 957–966.

Mar. Drugs 2015, 13
2043
6. Bear, B.; Asgian, J.; Termin, A.; Zimmermann, N. Small molecules targeting sodium and calcium
channels for neuropathic pain. Curr. Opin. Drug Discov. Dev. 2009, 12, 543–561.
7. Yamamoto, T.; Takahara, A. Recent updates of N-type calcium channel blockers with therapeutic
potential for neuropathic pain and stroke. Curr. Top. Med. Chem. 2009, 9, 377–395.
8. Zamponi, G.W.; Feng, Z.-P.; Zhang, L.; Pajouhesh, H.; Ding, Y.; Belardetti, F.; Pajouhesh, H.;
Dolphin, D.; Mitscher, L.A.; Snutch, T.P. Scaffold-based design and synthesis of potent N-type
calcium channel blockers. Bioorg. Med. Chem. Lett. 2009, 19, 6467–6472.
9. Abbadie, C.; McManus, O.B.; Sun, S.-Y.; Bugianesi, R.M.; Dai, G.; Haedo, R.J.; Herrington, J.B.;
Kaczorowski, G.J.; Smith, M.M.; Swensen, A.M.; et al. Analgesic effects of a substituted
N-triazole oxindole (Trox-1), a state-dependent, voltage-gated calcium channel 2 blocker.
J. Pharmacol. Exp. Ther. 2010, 334, 545–555.
10. Pajouhesh, H.; Feng, Z.-P.; Ding, Y.; Zhang, L.; Pajouhesh, H.; Morrison, J.-L.; Belardetti, F.;
Tringham, E.; Simonson, E.; Vanderah, T.W.; et al. Structure-activity relationships of
diphenylpiperazine N-type calcium channel inhibitors. Bioorg. Med. Chem. Lett. 2010, 20,
1378–1383.
11. Tyagarajan, S.; Chakravarty, P.K.; Park, M.; Zhou, B.; Herrington, J.B.; Ratliff, K.;
Bugianesi, R.M.; Williams, B.; Haedo, R.J.; Swensen, A.M.; et al. A potent and selective indole
N-type calcium channel (Cav2.2) blocker for the treatment of pain. Bioorg. Med. Chem. Lett.
2011, 21, 869–873.
12. Yamamoto, T.; Ohno, S.; Niwa, S.; Tokumasu, M.; Hagihara, M.; Koganei, H.; Fujita, S.-I.;
Takeda, T.; Saitou, Y.; Iwayama, S.; et al. Asymmetric synthesis and biological evaluations of
(+)- and (−)-6-dimethoxymethyl-1,4-dihydropyridine-3-carboxylic acid derivatives blocking
N-type calcium channels. Bioorg. Med. Chem. Lett. 2011, 21, 3317–3319.
13. Beebe, X.; Darczak, D.; Henry, R.F.; Vortherms, T.; Janis, R.; Namovic, M.; Donnelly-Roberts, D.;
Kage, K.L.; Surowy, C.; Milicic, I.; et al. Synthesis and SAR of 4-aminocyclopentapyrrolidines as
N-type Ca2+ channel blockers with analgesic activity. Bioorg. Med. Chem. 2012, 20, 4128–4139.
14. Scott, V.E.; Vortherms, T.A.; Niforatos, W.; Swensen, A.M.; Neelands, T.; Milicic, I.;
Banfor, P.N.; King, A.; Zhong, C.; Simler, G.; et al. A-1048400 is a novel, orally active,
state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception
without altering hemodynamic function in rats. Biochem. Pharmacol. 2012, 83, 406–418.
15. Subasinghe, N.L.; Wall, M.J.; Winters, M.P.; Qin, N.; Lubin, M.L.; Finley, M.F.A.; Brandt, M.R.;
Neeper, M.P.; Schneider, C.R.; Colburn, R.W.; et al. A novel series of pyrazolylpiperidine N-type
calcium channel blockers. Bioorg. Med. Chem. Lett. 2012, 22, 4080–4083.
16. Shao, P.P.; Ye, F.; Chakravarty, P.K.; Varughese, D.J.; Herrington, J.B.; Dai, G.; Bugianesi, R.M.;
Haedo, R.J.; Swensen, A.M.; Warren, V.A.; et al. Aminopiperidine sulfonamide Cav2.2 channel
inhibitors for the treatment of chronic pain. J. Med. Chem. 2012, 55, 9847–9855.
17. Pajouhesh, H.; Feng, Z.-P.; Zhang, L.; Pajouhesh, H.; Jiang, X.; Hendricson, A.; Dong, H.;
Tringham, E.; Ding, Y.; Vanderah, T.W.; et al. Structure-activity relationships of trimethoxybenzyl
piperazine N-type calcium channel inhibitors. Bioorg. Med. Chem. Lett. 2012, 22, 4153–4158.
18. Beebe, X.; Yeung, C.M.; Darczak, D.; Shekhar, S.; Vortherms, T.A.; Miller, L.; Milicic, I.;
Swensen, A.M.; Zhu, C.Z.; Banfor, P.; et al. Synthesis and SAR of 4-aminocyclopentapyrrolidines

Mar. Drugs 2015, 13
2044
as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain. Bioorg.
Med. Chem. Lett. 2013, 23, 4857–4861.
19. Borzenko, A.; Pajouhesh, H.; Morrison, J.-L.; Tringham, E.; Snutch, T.P.; Schafer, L.L. Modular,
efficient synthesis of asymmetrically substituted piperazine scaffolds as potent calcium channel
blockers. Bioorg. Med. Chem. Lett. 2013, 23, 3257–3261.
20. Shao, P.P.; Ye, F.; Chakravarty, P.K.; Herrington, J.B.; Dai, G.; Bugianesi, R.M.; Haedo, R.J.;
Swensen, A.M.; Warren, V.A.; Smith, M.M.; et al. Improved Cav2.2 channel inhibitors through a
gem-dimethylsulfone bioisostere replacement of a labile sulfonamide. ACS Med. Chem. Lett.
2013, 4, 1064–1068.
21. Xu, J.; Chu, K.L.; Zhu, C.Z.; Niforatos, W.; Swensen, A.; Searle, X.; Lee, L.; Jarvis, M.F.;
McGaraughty, S. A mixed Ca2+ channel blocker, A-1264087, utilizes peripheral and spinal
mechanisms to inhibit spinal nociceptive transmission in a rat model of neuropathic pain.
J. Neurophysiol. 2014, 111, 394–404.
22. Zhu, C.Z.; Vortherms, T.A.; Zhang, M.; Xu, J.; Swensen, A.M.; Niforatos, W.; Neelands, T.;
Milicic, I.; Lewis, L.G.; Zhong, C.; et al. Mechanistic insights into the analgesic efficacy of
A-1264087, a novel neuronal Ca2+ channel blocker that reduces nociception in rat preclinical pain
models. J. Pain 2014, 15, 387.e1–387.e14.
23. Mollica, A.; Costante, R.; Novellino, E.; Stefanucci, A.; Pieretti, S.; Zador, F.; Samavati, R.;
Borsodi, A.; Benyhe, S.; Vetter, I.; et al. Design, synthesis and biological evaluation of two opioid
agonist and Cav2.2 blocker multitarget ligands. Chem. Biol. Drug Des. 2014, doi:10.1111/cbdd.12479.
24. Duggan, P.J.; Faber, J.M.; Graham, J.E.; Lewis, R.J.; Lumsden, N.G.; Tuck, K.L. Synthesis and
Cav2.2 binding data for non-peptide mimetics of ω-conotoxin GVIA based on a
5-amino-anthranilamide core. Aust. J. Chem. 2008, 61, 11–15.
25. Andersson, A.; Baell, J.B.; Duggan, P.J.; Graham, J.E.; Lewis, R.J.; Lumsden, N.G.;
Tranberg, C.E.; Tuck, K.L.; Yang, A. ω-Conotoxin GVIA mimetics based on an anthranilamide
core: Effect of variation in ammonium side chain lengths and incorporation of fluorine.
Bioorg. Med. Chem. 2009, 17, 6659–6670.
26. Baell, J.B.; Duggan, P.J.; Forsyth, S.A.; Lewis, R.J.; Lok, Y.P.; Schroeder, C.I. Synthesis and
biological evaluation of nonpeptide mimetics of ω-conotoxin GVIA. Bioorg. Med. Chem. 2004,
12, 4025–4037.
27. Baell, J.B.; Duggan, P.J.; Forsyth, S.A.; Lewis, R.J.; Lok, Y.P.; Schroeder, C.I.; Shepherd, N.E.
Synthesis and biological evaluation of anthranilamide-based non-peptide mimetics of ω-conotoxin
GVIA. Tetrahedron 2006, 62, 7284–7292.
28. Duggan, P.J.; Lewis, R.J.; Lok, Y.P.; Lumsden, N.G.; Tuck, K.L.; Yang, A. Low molecular
weight non-peptide mimics of ω-conotoxin GVIA. Bioorg. Med. Chem. Lett. 2009, 19, 2763–2765.
29. Tranberg, C.E.; Yang, A.; Vetter, I.; McArthur, J.R.; Baell, J.B.; Lewis, R.J.; Tuck, K.L.;
Duggan, P.J. ω-Conotoxin GVIA mimetics that bind and inhibit neuronal Cav2.2 ion channels.
Mar. Drugs 2012, 10, 2349–2368.
30. Press release investors and media—zalicus. Available online: http://phx.corporate-ir.net/phoenix.
zhtml?c=148036&p=irol-newsArticle&ID=1874737&highlight= (accessed on 30 January 2015).
31. Lauri, G.; Bartlett, P. Caveat: A program to facilitate the design of organic molecules.
J. Comput. -Aided. Mol. Des. 1994, 8, 51–66.

Mar. Drugs 2015, 13
2045
32. Baell, J.; Forsyth, S.; Gable, R.; Norton, R.; Mulder, R. Design and synthesis of type-III mimetics
of ω-conotoxin GVIA. J. Comput. Aided. Mol. Des. 2001, 15, 1119–1136.
33. Aguilar, M.-I.; Purcell, A.W.; Devi, R.; Lew, R.; Rossjohn, J.; Smith, A.I.; Perlmutter, P. β-amino
acid-containing hybrid peptides-new opportunities in peptidomimetics. Org. Biomol. Chem. 2007,
5, 2884–2890.
34. Wen, F.; Zhang, H.; Yu, Z.; Jin, H.; Yang, Q.; Hou, T. Design, synthesis and antifungal/insecticidal
evaluation of novel nicotinamide derivatives. Pestic. Biochem. Physiol. 2010, 98, 248–253.
35. Bertrand, I.; Capet, M.; Lecomte, J.-M.; Levoin, N.; Ligneau, X.; Poupardin-Olivier, O.; Robert, P.;
Schwartz, J.-C.; Labeeuw, O. Preparation of pyrrolidinyl- and piperidinylpropoxyarenes as
histamine H3 receptor ligands. WO2006117609 A2, France, 9 November 2006.
36. Genzer, J.D.; Huttrer, C.P.; Wessem, G.C.V. Phenoxy- and benzyloxyalkyl thiocyanates. J. Am.
Chem. Soc. 1951, 73, 3159–3162.
37. Altin, J.G.; Banwell, M.G.; Coghlan, P.A.; Easton, C.J.; Nairn, M.R.; Offermann, D.A. Synthesis
of NTA3-DTDA—A chelator-lipid that promotes stable binding of His-tagged proteins to
membranes. Aust. J. Chem. 2006, 59, 302–306.
38. Bernatowicz, M.S.; Wu, Y.; Matsueda, G.R. 1H-Pyrazole-1-carboxamidine hydrochloride an
attractive reagent for guanylation of amines and its application to peptide synthesis. J. Org. Chem.
1992, 57, 2497–2502.
39. Sousa, S.R.; Vetter, I.; Ragnarsson, L.; Lewis, R.J. Expression and pharmacology of endogenous
Cav channels in SH-SY5Y human neuroblastoma cells. PLOS ONE 2013, 8, e59293.
40. McArthur, J.R.; Adams, D.J. RMIT University, Melbourne, Victoria, Australia. Personal
Communication, 2015. The SH-SY5Y FLIPR assay has previously been shown to be a good
predictor of Cav activity in other functional assays such as whole-cell patch clamp
electrophysiology measurements. Correspondingly, compound 6a was tested for its ability to
block calcium currents in HEK293 cells stably expressing human Cav2.2 channels, giving an IC50
of 36.3 ± 2.4 µM (n = 4–7).
41. Alvarez, S.G.; Alvarez, M.T. A practical procedure for the synthesis of alkyl azides at ambient
temperature in dimethyl sulfoxide in high purity and yield. Synthesis 1997, 1997, 413–414.
42. Evans, D.A.; Katz, J.L.; West, T.R. Synthesis of diaryl ethers through the copper-promoted
arylation of phenols with arylboronic acids. An expedient synthesis of thyroxine. Tetrahedron
Lett. 1998, 39, 2937–2940.
43. Bavin, P.M.G. The preparation of amines and hydrozo compounds using hydrazine and palladized
charcoal. Can. J. Chem. 1958, 36, 238–241.
44. Maiti, D.; Buchwald, S.L. Orthogonal Cu- and Pd-based catalyst systems for the O- and
N-arylation of aminophenols. J. Am. Chem. Soc. 2009, 131, 17423–17429.
45. Pajouhesh, H.; Lenz, G. Medicinal chemical properties of successful central nervous system
drugs. Neurotherapeutics 2005, 2, 541–553.
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).